Immunonkologie onkowissen

Developer: onkowissen

Category: Medical

Add App to Comparison

1.1K installs

Ratings not yet available

45 monthly active users

Revenue not available

Install Trends

Monthly +9.00

Steady

Immunonkologie onkowissen Summary

Immunonkologie onkowissen is a mobile Android app in Medical by onkowissen. Released in Oct 2019 (6 years ago). It has about 1.1K+ installs Based on AppGoblin estimates, it reaches roughly 45 monthly active users . Store metadata: updated Aug 28, 2025.

Store info: Last updated on Google Play on Aug 28, 2025 .

SDKs, Trackers & Permissions

App not yet scanned for SDKs.

App Details

Store ID: de.onkowissen.immunonkologie

First Released: 2019-10-07

Store Last Updated: 2025-08-28

In-App Purchases: No

Ads: No

Website: immunonkologie.onkowissen.de

App Store

Crawl Status: Success

AppGoblin First Crawled: 2024-08-26

AppGoblin Last Crawled: 2026-03-07

Ads & App-Ads.txt

App does not have ads.

AppGoblin SDK Scans

App not yet analyzed for SDKs.

The download and scan process is automated but can require manual troubleshooting. Feel free to reach out if your request does not complete in 24hrs or if you have any questions.

0★

Ratings: 0

5★

4★

3★

2★

1★

Screenshots

App Description

The app "onkowissen Immuno-Oncology": innovative - interactive - educational

The onkowissen Immuno-Oncology app offers you digital, quick and easy access to extensive information about the indications, effectiveness and therapy management of checkpoint inhibitors. The app was developed and implemented in cooperation with medical experts.

Find answers to your questions on the following topics:
• Mechanisms of the immune response
• Checkpoint inhibition
• Biomarkers
• Effectiveness by entity
• Approved Substances
• Management of immune-mediated side effects
• Tools & Services

The app also contains a news feed with links to new data and current topics related to immuno-oncology.

This app is intended only for professionals with an onkowissen.de login. The app is intended solely as a source of information about therapy with checkpoint inhibitors.